Karyopharm Therapeutics | KPTI - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 688M 58M 2026-09
Abbott USD 297M 2M 2026-09
Amgen USD 653M 94.99B 2026-09
AstraZeneca USD 371M 31M 2026-09
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Bristol-Myers Squibb USD 403M 4M 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
GlaxoSmithKline GBP 219M 98M 2026-09
Incyte USD 605K 23K 2026-09
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.4M 493K 2026-06
Merck USD 525M 46M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Novartis USD 468M 6M 2026-09
Novartis USD 281M 8M 2025-09
Pfizer USD 662M 5M 2026-09
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Takeda JPY 63.38B 466M 2026-09
Tectonic Therapeutic USD 237.03M 9.54M 2026-06
TG Therapeutics USD 16.57M 8.91M 2026-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Xencor USD 4.11M 3.24M 2026-09